CHP Merger Corp. Files $250M SPAC
by Kristi Marvin on 2019-11-02 at 7:14pm

Thursday evening, CHP Merger Corp. (CHPMU), filed their $250 million SPAC for IPO, focusing on the healthcare and healthcare related industries.  CHP will led by Joseph Swedish, as Chairman, and James Olsen, as CEO and Director.  Both Mr. Swedish and Mr. Olsen have considerable experience in the healthcare field as both operators and deal makers.

Mr. Swedish, in particular, has some very recognizable names on his CV.  Notable previous experience includes being the former Chairman, President and CEO of Anthem, Inc., the largest for-profit managed health care company in the Blue Cross Blue Shield Association. A quick search on the Google machine will bring back high praise for his tenure at Anthem and that while CEO, Anthem’s membership grew by four million, or 11 percent.  Additionally, the average share price nearly quadrupled from approximately $60 per share to $250 per share. Furthermore, Mr. Swedish is a co-founder of Concord Health Partners, LLC (the “CHP” in CHP Merger Corp.), a healthcare investment firm, along with Mr. Olsen (also a co-founder). Prior to founding Concord in 2017, Mr. Olsen was Managing Director & Head of Not-for-Profit Healthcare Investment Banking at Jefferies Group LLC.  So once again, we have a nice pairing of an operator and deal-maker, which has generally yielded great SPAC combination results.

With the team’s credentials in mind, let’s look at the terms. This is a 24 months, 100% in trust, 1/2 warrant structure, but even though they are not opting for the 1/3 warrant of A++ teams, they’ve added an extra bell and whistle befitting their top notch backgrounds.  That is, CHP can call their warrants at $10.00 for shares, plus $0.10 per warrant, which is a very “A++ term”.   However, like many of the recent SPACs that have filed to IPO (which many have also been high quality teams), they are new to SPACs.  As such, they are debuting with the investor-friendly strategy of including a 1/2 warrant. Which is interesting because only six months ago, anybody who was “anybody” insisted they needed a 1/3 warrant.  But now, it’s almost the opposite.  There’s more bravado in saying a 1/2 warrant versus a 1/3 is not going to be a hindrance to bringing a great SPAC combination.  To quote Blazing Saddles (or Treasure of the Sierra Madre if you’re more high-class) it’s more like, “1/3 warrant?! We don’t need no stinkin’ 1/3 warrant”.

Lastly, we also have a VERY tier-1 underwriting team.  This is JP Morgan’s first left lead SPAC, but it’s an auspicious debut.  And not only that, but we have Credit Suisse on the underwriting team (always a SPAC powerhouse) and Morgan Stanley, which recently hired Goldman’s SPAC banker.  As a result, CHP should be an easy sell with big-time demand.  Look for this SPAC to price just ahead of Thanksgiving.

Summary of terms below:

CHP Merger terms 11-2-19

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-22 at 3:01pm

With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...

by Nicholas Alan Clayton on 2024-04-22 at 7:51am

At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...

by Kristi Marvin on 2024-04-20 at 11:45am

Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...

by Nicholas Alan Clayton on 2024-04-19 at 3:00pm

Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...

by Nicholas Alan Clayton on 2024-04-19 at 7:53am

At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved